Conclusion
Evaluating clinical studies on ovarian response, the initial hMG dose should be 150 IU hMG/day in IVF programs without GnRH cotreatment and 225 IU hMG/day in IVF programs with cotreatment with GnRH-a. Age (>35 years), basal FSH level, and body weight are variables known to affect ovarian response and, therefore, reasons to consider an increase in the initial hMG dose. In addition to a good ovarian response, ovarian stimulation with 150 IU/hMG may restrict possible adverse effects of high-dose hMG treatment on the endometrium and on the oocyte (1,12,13). Let us hope that in the future prospective randomized studies will be available to answer questions on the optimal hMG dose in different stimulation protocols.
This is a preview of subscription content, log in via an institution to check access.
References
Ben Rafael Z, Benadiva CA, Ausmanas M, Barber B, Blasco L, Flickinger GL, Mastroianni LJ: Dose of human menopausal gonadotropin influences the outcome of an in vitro fertilization program. Fertil Steril 1987;48:964–968
Ben Rafael Z, Lipitz S, Bider D, Mashiach S: Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 1991; 55:272–275
Blankstein J, Collins RL, Easley KA, Quigley MM: Increased human menopausal gonadotropin dose during the early follicular phase: Effect on follicular recruitment and treatment outcome. J Vitro Fert Embryo Transfer 1989;6:112–117
Hershlag A, Asis MC, Diamond MP, DeCherney AH, Lavy G: The predictive value and the management of cycles with low initial estradiol levels. Fertil Steril 1990;53:1064–1067
van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA: Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: A randomized study. Hum Reprod 1993;8:369–373
Schoemaker J, van Weissenbruch MM, Scheele F, van der Meer M: The FSH threshold concept in clinical ovulation induction. Bailliere's Clin Obstet Gynaecol 1994;7:297–308
Schoemaker J, van Weissenbruch MM, Scheele F, van der Meer M: The use of GnrH Analogues in IVF-ET in the light of the FSH-threshold principle. Perspectives on assisted reproduction. Frontiers Endocrinol 1994;4:423–429
Benadiva CA, Ben Rafael Z, Blasco L, Tureck R, Mastroianni LJ, Flickinger GL: An increased initial follicle-stimulating hormone/luteinizing hormone ratio does not affect ovarian responses and the outcomes of in vitro fertilization. Fertil Steril 1988;50:777–781
Benadiva CA, Ben Rafael Z, Strauss JF, Mastroianni LJ, Flickinger GL: Ovarian response of individuals to different doses of human menopausal gonadotropin. Fertil Steril 1988;49:997–1001
Karande VC, Jones GS, Veeck LL, Muasher SJ: High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil Steril 1990;53: 486–489
Pantos C, Thornton SJ, Speirs AL, Johnston I: Increasing the human menopausal gonadotropin dose—Does the response really improve? Fertil Steril 1990;53:436–439
Halme J, Hammond MG, Bailey L, Talbert LM: Lower doses of human menopausal gonadotropin are associated with improved success with in vitro fertilization in women with low improved success with in vitro fertilization in women with low body weight. Am J Obstet Gynecol 1988;158:64–65
Stadtmauer L, Ditkoff EC, Session D, Kelly A: High dosages of gonadotropins are associated with poor pregnancy out-comes after in vitro fertilization-embryo transfer. Fertil Steril 1994;61:1058–1064
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Hooff, M.H.A. The human menopausal gonadotropin (hMG) dose in in vitro fertilization (IVF): What is the optimal dose?. J Assist Reprod Genet 12, 233–235 (1995). https://doi.org/10.1007/BF02212923
Issue Date:
DOI: https://doi.org/10.1007/BF02212923